Table 2.
Clinical and biochemical characteristics of participants with type 2 diabetes
| Normo | Micro | Macro | P | |
|---|---|---|---|---|
| n | 112 | 70 | 34 | |
| Age, years | 66±11 | 67±14 | 66±9 | 0.78 |
| Male, % | 52 | 65 | 68 | |
| Diabetes duration, years | 13±8 | 14±10 | 13±8 | 0.41 |
| BMI | 31±6 | 32±6 | 35±9 | 0.06 |
| Systolic blood pressure mm Hg | 137±18 | 136±17 | 139±17 | 0.64 |
| Fasting glucose, mmol/1 | 8.7±2.3 | 8.2±2.2 | 9.6±4.0 | 0.42 |
| HbA1c, % | 7.5±1.0 | 7.8±1.6 | 8.0±1.6 | 0.19 |
| AER, μg/min | 6.9×/÷1.9 | 51.0×/÷2.0 | 688.1×/÷2.1 | |
| iGFR, ml/min/1.73m2 | 66.8±18.4 | 67.2±21.0 | 58.7±20.9 | 0.09 |
| Total cholesterol, mmol/l | 4.3±1.1 | 4.3±1.1 | 4.2±1.1 | 0.87 |
| LDL-cholesterol, mmol/l | 2.5±0.9 | 2.6±1.2 | 2.5±0.9 | 0.67 |
| HDL-cholesterol, mmol/l | 1.1±0.4 | 1.0±0.3 | 1.1±0.5 | 0.22 |
| Triglycérides, mmol/1 | 1.5±0.9 | 1.8±1.2 | 1.7±1.0 | 0.13 |
| Medication use, % | ||||
| ACE inhibitors | 52 | 60 | 60 | 0.77 |
| ARBs | 39 | 46 | 67 | 0.18 |
| β-Blockers | 36 | 28 | 53 | 0.27 |
| Diuretics | 41 | 50 | 54 | 0.69 |
| Statins | 74 | 88 | 86 | 0.39 |
Data are means 8 SD except for AER, which is shown as the geometric mean ×/÷ tolerance factor and medication use, which is displayed as % use. ACE = Angiotensin-converting enzyme; ARB = angiotensin receptor blocker; HbA1c = glycated hemoglobin; iGFR = isotopic GFR.